Houston, Texas 77054

  • HIV Infections


To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.


Inclusion Criteria Patients must have: - HIV-1 seropositivity. - Absolute number of T4 cells 100-300 cells/mm3. - Given informed consent. - Zidovudine (AZT) therapy for 6 months prior to study entry. - At least one of the listed HIV-related clinical symptoms or opportunistic infections: - weight loss > 10 percent, unexplained diarrhea, unexplained intermittent fever, oral candidiasis > 1 month, decreased Karnofsky, oral hairy leukoplakia, chronic fatigue. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Evidence of AIDS. - Intercurrent acute medical disorder. Concurrent Medication: Excluded: - Chemotherapy for Kaposi's sarcoma (KS). - Aspirin. - Non-steroidal anti-inflammatory drugs. Patients with the following are excluded: - Inability to return for treatment and evaluation for 12 months. - Intercurrent acute medical disorder. - Evidence of AIDS. - Receiving chemotherapy for Kaposi's sarcoma (KS). - Unwilling or unable to give informed consent. Required: - Zidovudine (AZT). Required at least 6 months prior to study entry: - Zidovudine (AZT). Active drug abuse.



Primary Contact:


Backup Contact:


Location Contact:

Houston, Texas 77054
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: July 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.